Enanta reports Q4 net loss $28.1M; initiates EDP-323 Phase 2a RSV study

ENANTA PHARMACEUTICALS INC

2023-FY EPS reported -$6.38 revenue$79,204,000

Q4 revenue $18.9M (down from $20.3M YoY); FY revenue $79.2M (down from $86.2M).
Net loss $28.1M ($1.33/diluted share) vs $26.3M ($1.27) in Q4 2022; FY loss $133.8M ($6.38) vs $121.8M ($5.91).
Cash and marketable securities $370M; expects to fund operations through fiscal 2027.
FY2024 guidance: R&D $100-120M (down from $163.5M actual), G&A $45-50M (down from $52M).
Initiated Phase 2a challenge study for RSV candidate EDP-323; data expected Q3 2024. Advancing EDP-938 Phase 2 trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENANTA PHARMACEUTICALS INC updated its fiscal fourth quarter and year ended September 30, 2023 guidance (lowered).

Period: fiscal fourth quarter and year ended September 30, 2023
Guidance: lowered
Result: reported results

Exact text from the filing

On November 20, 2023, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2023.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-065087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.